rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

GNBT !!!

2.656 Posts
Pagina: «« 1 ... 118 119 120 121 122 ... 133 »» | Laatste | Omlaag ↓
  1. [verwijderd] 24 april 2006 20:34

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Hoop het,laatste tijd veel bijgekocht,rond de 2,60,en sta door die stijging van de euro nog steeds op verlies,wij kopen eigenlijk dollars met onze euros als die euro dan gaat stijgen is dat ook een verlies.
  4. [verwijderd] 1 mei 2006 14:18

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Press Release Source: Generex Biotechnology

    Generex Biotechnology Subsidiary Receives Patent From European Patent Office
    Monday May 1, 7:30 am ET

    Award in Ii-Key Hybrids Technology to Regulate Antigen Presentation by Immunoregulatory Cells

    TORONTO--(MARKET WIRE)--May 1, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News) announced today that its wholly owned subsidiary, Antigen Express, Inc., has been granted a European patent titled "Regulation of Antigen Presentation." The patent issued on December 21, 2005 relates to the use of Ii-Key peptides in regulating antigen presentation. It broadly covers the use of Ii-Key in potential immunotherapy treatments of cancer and infectious diseases.
    ADVERTISEMENT


    Antigen Express is pursuing novel immunotherapeutics based on the antigen-specific stimulation of T helper cells. The use of Ii-Key to augment the potency of antigenic peptides constitutes one of two platform technologies being developed at the Company. The most advanced of these projects employs an Ii-Key modified peptide from the tumor-associated HER-2/neu protein. That compound has been in the clinic for a year in patients with breast cancer and has shown good activity in stimulating T helper cells to specifically recognize HER-2/neu. A similar vaccine employing Ii-Key and a fragment of the H5 protein from the H5N1 virus is being developed as a prophylactic vaccine for the potentially pandemic H5N1 avian influenza virus.

    About Generex

    Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.

    For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

    Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

    Contact:
    Contact:
    Shayne Gilliatt
    Generex Biotechnology Corporation
    Phone: (800) 391-6755 and (416) 364-2551

    Ed Lewis
    CEOcast, Inc.
    Phone: 1 (212) 732-4300


    --------------------------------------------------------------------------------
    Source: Generex Biotechnology
  14. [verwijderd] 1 mei 2006 19:23

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Smike schreef:

    Toepie, wat dacht je van het uitgegeven persbericht?
    Ach, die was voorbeurs al!

    Reactie komt daarvoor te laat...
    Ik denk combi persbericth en shorts die moeten coveren...
  15. jurpsy 1 mei 2006 22:15

    • jurpsy

      Lid sinds: 22 nov 2004

      Laatste bezoek: 30 mrt 2025

    • Aanbevelingen

      Ontvangen: 1287

      Gegeven: 9705

    •    Aantal posts: 1.168

    Laatste 3,09 22:00 500
    +/- 0,43 16,17%
    Open 2,74 15:30
    Slot 2,66 -
    Hoog 3,11 21:58
    Laag 2,68 15:30
    Volume 17.420.887
  17. [verwijderd] 2 mei 2006 14:38

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    PB!

    Clinician Presents Generex Oral-lyn(TM) Clinical Data at the Pediatric Academic Societies' 2006 Annual Meeting
    Tuesday May 2, 8:00 am ET

    PREMARKET:

    Pre-Market Trade Reporting Tuesday May 02


    Pre-Market
    Last: $ 3.13 Pre-Market
    High: $ 3.15
    Pre-Market
    Volume: 135,767 Pre-Market
    Low: $ 3.06

    Pre-Market
    Time (ET) Pre-Market
    Price Pre-Market
    Share Volume
    08:36 $ 3.15 1,000
    08:36 $ 3.14 175
    08:36 $ 3.14 1,000
    08:36 $ 3.14 3,825
    08:36 $ 3.15 500
    08:36 $ 3.14 1,175
    08:36 $ 3.14 100
    08:36 $ 3.14 1,800
    08:36 $ 3.14 100
    08:36 $ 3.14 1,000
    08:36 $ 3.14 2,000
    08:36 $ 3.14 100
    08:36 $ 3.13 7,000
    08:34 $ 3.15 1,000
    08:34 $ 3.15 2,000
    08:34 $ 3.15 500
    08:33 $ 3.14 2,000
    08:33 $ 3.14 900
    08:33 $ 3.14 900
    08:33 $ 3.14 200
    08:33 $ 3.14 1,000
    08:33 $ 3.15 1,000
    08:33 $ 3.15 1,000
    08:33 $ 3.15 2,500
    08:33 $ 3.15 1,000
    08:33 $ 3.15 1,100
    08:33 $ 3.15 1,420
    08:33 $ 3.15 2,368
    08:32 $ 3.13 1,500
    08:32 $ 3.13 100
    08:32 $ 3.13 500
    08:32 $ 3.13 1,000
    08:32 $ 3.13 1,900
    08:32 $ 3.13 100
    08:32 $ 3.13 1,900
    08:32 $ 3.13 1,000
    08:31 $ 3.13 1,901
    08:31 $ 3.14 2,000
    08:31 $ 3.14 901
    08:31 $ 3.14 2,000
    08:31 $ 3.14 1,000
    08:30 $ 3.12 1,000
    08:29 $ 3.12 501
    08:29 $ 3.14 1,400
    08:29 $ 3.13 901
    08:29 $ 3.12 1,000
    08:28 $ 3.09 2,135
    08:28 $ 3.09 300
    08:28 $ 3.09 300
    08:28 $ 3.10 2,000


2.656 Posts
Pagina: «« 1 ... 118 119 120 121 122 ... 133 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.124
AB InBev 2 5.538
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.217
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.877
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.848
Aedifica 3 926
Aegon 3.258 323.086
AFC Ajax 538 7.092
Affimed NV 2 6.305
ageas 5.844 109.906
Agfa-Gevaert 14 2.063
Ahold 3.538 74.353
Air France - KLM 1.025 35.295
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.051
Alfen 16 25.306
Allfunds Group 4 1.517
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 425
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.959
AMG 971 134.455
AMS 3 73
Amsterdam Commodities 305 6.745
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 496
Antonov 22.632 153.605
Aperam 92 15.063
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.807
Arcelor Mittal 2.034 320.999
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.355
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.623
ASML 1.766 110.334
ASR Nederland 21 4.513
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.959
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449